Published in Antimicrob Agents Chemother on February 01, 2006
Melanized fungi in human disease. Clin Microbiol Rev (2010) 2.89
Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol (2010) 1.03
Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol (2011) 0.99
In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob Agents Chemother (2007) 0.90
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agents Chemother (2007) 0.87
Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms. Parasitol Res (2012) 0.86
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob Agents Chemother (2012) 0.86
Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri. Antimicrob Agents Chemother (2008) 0.86
Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy. Parasit Vectors (2011) 0.83
Synthesis and antifungal activities of miltefosine analogs. Bioorg Med Chem Lett (2013) 0.82
Role of phospholipases in fungal fitness, pathogenicity, and drug development - lessons from cryptococcus neoformans. Front Microbiol (2010) 0.81
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother (2015) 0.78
Miltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity. Antimicrob Agents Chemother (2014) 0.78
The antifungal pipeline: a reality check. Nat Rev Drug Discov (2017) 0.77
Evaluation of the effect of miltefosine on Trichomonas vaginalis. Parasitol Res (2013) 0.76
In vitro combination of voriconazole and miltefosine against clinically relevant molds. Antimicrob Agents Chemother (2014) 0.76
Molecular and functional characterization of the ceramide synthase from Trypanosoma cruzi. Mol Biochem Parasitol (2011) 0.75
A P4 - ATPase subunit of the Cdc50 family plays a role in iron acquisition and virulence in Cryptococcus neoformans. Cell Microbiol (2017) 0.75
A rapid method of total lipid extraction and purification. Can J Biochem Physiol (1959) 173.74
Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 6.94
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis (2004) 1.81
Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis (1997) 1.72
Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun (2004) 1.66
Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun (2003) 1.55
Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis (2003) 1.53
Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans. Infect Immun (1997) 1.45
Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania. Mol Biochem Parasitol (2000) 1.23
Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol (2003) 1.21
Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem J (2000) 1.19
Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun (1996) 1.14
Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect (2006) 1.11
In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 1.11
Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem (1998) 1.06
Biochemical and functional characterisation of secreted phospholipase activities from Cryptococcus neoformans in their naturally occurring state. J Med Microbiol (1999) 1.04
Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans. Biochim Biophys Acta (1995) 1.04
Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. J Biol Chem (1992) 0.99
Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv Exp Med Biol (1996) 0.95
Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol (2002) 0.94
Distribution and metabolism of hexadecylphosphocholine in mice. Lipids (1987) 0.94
Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother Pharmacol (1992) 0.93
Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem Pharmacol (2001) 0.93
Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol (2003) 0.90
Phospholipid analogues: side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis. J Lipid Res (1994) 0.89
Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat (1992) 0.87
Synthesis and antiproliferative activity of alkylphosphocholines. Chem Phys Lipids (2003) 0.85
Lysophospholipase 1 in Trypanosoma brucei. Tropenmed Parasitol (1981) 0.84
Synthetic analogues of irlbacholine: a novel antifungal plant metabolite isolated from Irlbachia alata. J Nat Prod (1999) 0.83
The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur J Cancer (1991) 0.83
Phospholipase A2 inhibitors: monoacyl, monoacylamino-glycero-phosphocholines. Biochem Soc Trans (1989) 0.81
Antiprotozoal lysophospholipid analogues: a comparison of their activity against trypanosomatid parasites and tumor cells. Mini Rev Med Chem (2004) 0.79
Inhibition of GPI phospholipase C from Trypanosoma brucei by fluoro-inositol dodecylphosphonates. Biochem Biophys Res Commun (1998) 0.77
Miltefosine Zentaris. Curr Opin Investig Drugs (2002) 0.77
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis (2013) 2.17
Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis (2013) 1.76
Echinocandin antifungal drugs in fungal infections: a comparison. Drugs (2011) 1.67
Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med (2008) 1.50
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother (2010) 1.34
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother (2006) 1.34
Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One (2012) 1.31
Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics (2009) 1.25
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis (2009) 1.22
Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. Eukaryot Cell (2006) 1.21
Antifungal therapy in invasive fungal infections. Curr Opin Pharmacol (2010) 1.18
Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol (2009) 1.17
secA1 gene sequence polymorphisms for species identification of Nocardia species and recognition of intraspecies genetic diversity. J Clin Microbiol (2010) 1.15
Simultaneous detection and identification of Candida, Aspergillus, and Cryptococcus species by reverse line blot hybridization. J Clin Microbiol (2006) 1.12
Antifungal agents. Med J Aust (2007) 1.12
Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. J Biol Chem (2007) 1.11
Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. J Clin Microbiol (2008) 1.10
Identification of metabolites of importance in the pathogenesis of pulmonary cryptococcoma using nuclear magnetic resonance spectroscopy. Microbes Infect (2003) 1.10
Secretion of cryptococcal phospholipase B1 (PLB1) is regulated by a glycosylphosphatidylinositol (GPI) anchor. Biochem J (2005) 1.10
Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis (2012) 1.09
Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care (2009) 1.06
Reverse line blot hybridization assay for identification of medically important fungi from culture and clinical specimens. J Clin Microbiol (2007) 1.05
Practical method for detection and identification of Candida, Aspergillus, and Scedosporium spp. by use of rolling-circle amplification. J Clin Microbiol (2008) 1.01
Role and mechanism of phosphatidylinositol-specific phospholipase C in survival and virulence of Cryptococcus neoformans. Mol Microbiol (2008) 1.01
KRE genes are required for beta-1,6-glucan synthesis, maintenance of capsule architecture and cell wall protein anchoring in Cryptococcus neoformans. Mol Microbiol (2010) 1.01
Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII. Mycopathologia (2011) 0.99
Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts. J Med Chem (2006) 0.98
Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. Emerg Infect Dis (2008) 0.97
Three-locus identification, genotyping, and antifungal susceptibilities of medically important Trichosporon species from China. J Clin Microbiol (2011) 0.97
Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med (2009) 0.97
Isolation and characterisation of the phospholipase B gene of Cryptococcus neoformans var. gattii. FEMS Yeast Res (2002) 0.96
Association between fertility and molecular sub-type of global isolates of Cryptococcus gattii molecular type VGII. Med Mycol (2008) 0.96
Assignment of reference 5'-end 16S rDNA sequences and species-specific sequence polymorphisms improves species identification of Nocardia. Open Microbiol J (2009) 0.96
Whole-genome characterization and genotyping of global WU polyomavirus strains. J Virol (2010) 0.96
Strain-dependent effects of environmental signals on the production of extracellular phospholipase by Cryptococcus neoformans. FEMS Microbiol Lett (2002) 0.95
Rapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy. Appl Environ Microbiol (2003) 0.94
Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol (2010) 0.94
Identification of pathogenic Nocardia species by reverse line blot hybridization targeting the 16S rRNA and 16S-23S rRNA gene spacer regions. J Clin Microbiol (2009) 0.93
PCR-restriction fragment length polymorphism analysis of the phospholipase B (PLB1) gene for subtyping of Cryptococcus neoformans isolates. Appl Environ Microbiol (2003) 0.93
Pneumonia and lung infections due to emerging and unusual fungal pathogens. Semin Respir Crit Care Med (2011) 0.93
The Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity. PLoS One (2012) 0.91
Cryptococcal phospholipases: a novel lysophospholipase discovered in the pathogenic fungus Cryptococcus gattii. Biochem J (2004) 0.90
Practical identification of eight medically important Trichosporon species by reverse line blot hybridization (RLB) assay and rolling circle amplification (RCA). Med Mycol (2012) 0.89
Cloning of CnLYSO1, a novel extracellular lysophospholipase of the pathogenic fungus Cryptococcus neoformans. Gene (2003) 0.89
Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase. Mol Pharmacol (2011) 0.89
Colony multiplex-tandem PCR for rapid, accurate identification of fungal cultures. J Clin Microbiol (2008) 0.88
The many faces of the adamantyl group in drug design. Eur J Med Chem (2011) 0.88
N-linked glycosylation sites affect secretion of cryptococcal phospholipase B1, irrespective of glycosylphosphatidylinositol anchoring. Biochim Biophys Acta (2006) 0.88
Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol (2010) 0.87
In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agents Chemother (2007) 0.87
Cryptococcal lipid metabolism: phospholipase B1 is implicated in transcellular metabolism of macrophage-derived lipids. Eukaryot Cell (2006) 0.87
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob Agents Chemother (2012) 0.86
Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities. Emerg Infect Dis (2017) 0.86
In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens. J Antimicrob Chemother (2013) 0.85
Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care (2010) 0.85
Identification of Aph1, a phosphate-regulated, secreted, and vacuolar acid phosphatase in Cryptococcus neoformans. MBio (2014) 0.84
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload. J Med Chem (2010) 0.84
Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model. Mycopathologia (2010) 0.84
Management of invasive candidiasis in the intensive care unit. Drugs (2010) 0.84
Human rhinovirus C in adult haematopoietic stem cell transplant recipients with respiratory illness. J Clin Virol (2013) 0.83
Inhibition of tetraphenylphosphonium-induced NMR-visible lipid accumulation in human breast cells by chlorpromazine. Biochim Biophys Acta (2003) 0.83
Identification of Staphylococcus aureus brain abscesses: rat and human studies with 1H MR spectroscopy. Radiology (2005) 0.83
Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes. Bioorg Med Chem (2009) 0.82
Unique biological properties and molecular mechanism of 5,6-bridged quinolones. Antimicrob Agents Chemother (2003) 0.81
Fungal Inositol Pyrophosphate IP7 Is Crucial for Metabolic Adaptation to the Host Environment and Pathogenicity. MBio (2015) 0.81
Phospholipase C of Cryptococcus neoformans regulates homeostasis and virulence by providing inositol trisphosphate as a substrate for Arg1 kinase. Infect Immun (2013) 0.80
Rapid etiological classification of meningitis by NMR spectroscopy based on metabolite profiles and host response. PLoS One (2009) 0.80
Cerebral nocardiosis characterized by magnetic resonance spectroscopy in vivo. Clin Infect Dis (2002) 0.80
Synthesis, antifungal and antimicrobial activity of alkylphospholipids. Bioorg Med Chem (2007) 0.80
Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes. Bioorg Med Chem (2007) 0.80
Optimizing therapy for Candida infections. Semin Respir Crit Care Med (2007) 0.80
Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leuk Lymphoma (2011) 0.79
Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy. Antimicrob Agents Chemother (2006) 0.79
In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. Antimicrob Agents Chemother (2010) 0.79
Cutaneous zygomycosis caused by Saksenaea vasiformis following water-related wound in a 24-year-old immunocompetent woman. Mycoses (2009) 0.78
A rapid screening test to distinguish between Candida albicans and Candida dubliniensis using NMR spectroscopy. FEMS Microbiol Lett (2005) 0.78
Functional characterization of the hexose transporter Hxt13p: an efflux pump that mediates resistance to miltefosine in yeast. Fungal Genet Biol (2013) 0.78
Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. BMC Microbiol (2009) 0.78
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free Radic Biol Med (2013) 0.77